Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.

@article{Claus2005EpigeneticTO,
  title={Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.},
  author={Raymond Claus and Maika Almstedt and Michael Charles Luebbert},
  journal={Seminars in oncology},
  year={2005},
  volume={32 5},
  pages={
          511-20
        }
}
Although the first studies using DNA demethylating agents at low doses in hematologic neoplasia and hemoglobinopathies were initiated more than 20 years ago, development of this type of nonintensive treatment has only been spurred in the last 6 to 8 years by the discovery of many genes that are specifically hypermethylated in cancer. These provide a powerful rationale for using azanucleosides (and other small molecules being developed for DNA demethylation) as a novel means of pharmacologic… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Secreted frizzled related proteins: Implications in cancers.

  • Biochimica et biophysica acta
  • 2014
VIEW 11 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Up-Regulation of Lamin A / C Expression in Epstein-Barr Virus Immortalized B Cells and Burkitt Lymphoma Cell Lines of Activated B Cell Phenotype

Ferenc Bánáti, Anita Koroknai, +12 authors Hans-Helmut Niller
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND